Literature DB >> 8873639

Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.

.   

Abstract

OBJECTIVE: To recommend clinical practice guidelines for the assessment of people at risk for osteoporosis, and for effective diagnosis and management of the condition. OPTIONS: Screening and diagnostic methods: risk-factor assessment, clinical evaluation, measurement of bone mineral density, laboratory investigations. Prophylactic and corrective therapies: calcium and vitamin D nutritional supplementation, physical activity and fall-avoidance techniques, ovarian hormone therapy, bisphosphonate drugs, other drug therapies. Pain-management medications and techniques. OUTCOMES: Prevention of loss of bone mineral density and fracture; increased bone mass; and improved quality of life. EVIDENCE: Epidemiologic and clinical studies and reports were examined, with emphasis on recent randomized controlled trials. Clinical practice in Canada and elsewhere was surveyed. Availability of treatment products and diagnostic equipment in Canada was considered. VALUES: Cost-effective methods and products that can be adopted across Canada were considered. A high value was given to accurate assessment of fracture risk and osteoporosis, and to increasing bone mineral density, reducing fractures and fracture risk and minimizing side effects of diagnosis and treatment. BENEFITS, HARMS AND COSTS: Proper diagnosis and management of osteoporosis minimize injury and disability, improve quality of life for patients and reduce costs to society. Rationally targeted methods of screening and diagnosis are safe and cost effective. Harmful side effects and costs of recommended therapies are minimal compared with the harms and costs of untreated osteoporosis. Alternative therapies provide a range of choices for physicians and patients. RECOMMENDATIONS: Population sets at high risk should be identified and then the diagnosis confirmed through bone densitometry. Dual-energy x-ray absorptiometry is the preferred measurement technique. Radiography can be adjunct when indicated. Calcium and vitamin D nutritional supplementation should be at currently recommended levels. Patients should be counselled in fall-avoidance techniques and exercises. Immobilization should be avoided. Guidelines for management of acute pain are listed. Ovarian hormone therapy is the therapy of choice for osteoporosis prevention and treatment in postmenopausal women. Bisphosphonates are an alternative therapy for women with established osteoporosis who cannot or prefer not to take ovarian hormone therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8873639      PMCID: PMC1335371     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  128 in total

1.  The effect of estrogen dose on postmenopausal bone loss.

Authors:  A Horsman; M Jones; R Francis; C Nordin
Journal:  N Engl J Med       Date:  1983-12-08       Impact factor: 91.245

2.  The minimum effective dose of estrogen for prevention of postmenopausal bone loss.

Authors:  R Lindsay; D M Hart; D M Clark
Journal:  Obstet Gynecol       Date:  1984-06       Impact factor: 7.661

3.  Noncontraceptive estrogen use and the risk of breast cancer.

Authors:  D W Kaufman; D R Miller; L Rosenberg; S P Helmrich; P Stolley; D Schottenfeld; S Shapiro
Journal:  JAMA       Date:  1984-07-06       Impact factor: 56.272

4.  Regulation of bone formation by applied dynamic loads.

Authors:  C T Rubin; L E Lanyon
Journal:  J Bone Joint Surg Am       Date:  1984-03       Impact factor: 5.284

5.  Long-term estrogen replacement therapy prevents bone loss and fractures.

Authors:  B Ettinger; H K Genant; C E Cann
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

6.  Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy.

Authors:  H K Genant; C E Cann; B Ettinger; G S Gordan
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

7.  Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment.

Authors:  R S Weinstein; G F Bryce; L J Sappington; D W King; B B Gallagher
Journal:  J Clin Endocrinol Metab       Date:  1984-06       Impact factor: 5.958

Review 8.  Calcium nutrition and bone health in the elderly.

Authors:  R P Heaney; J C Gallagher; C C Johnston; R Neer; A M Parfitt; G D Whedon
Journal:  Am J Clin Nutr       Date:  1982-11       Impact factor: 7.045

9.  Steroid-induced fractures and bone loss in patients with asthma.

Authors:  A D Adinoff; J R Hollister
Journal:  N Engl J Med       Date:  1983-08-04       Impact factor: 91.245

Review 10.  Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review.

Authors:  R D Gambrell; C A Bagnell; R B Greenblatt
Journal:  Am J Obstet Gynecol       Date:  1983-07-15       Impact factor: 8.661

View more
  25 in total

1.  Influence of bone densitometry results on the treatment of osteoporosis.

Authors:  N S Fitt; S L Mitchell; A Cranney; K Gulenchyn; M Huang; P Tugwell
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

2.  Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.

Authors:  Anthony B Hodsman; David A Hanley; Robert Josse
Journal:  CMAJ       Date:  2002-05-28       Impact factor: 8.262

Review 3.  Burden of osteoporosis and fractures in developing countries.

Authors:  Anthony D Woolf; Bruce Pfleger
Journal:  Curr Osteoporos Rep       Date:  2005-09       Impact factor: 5.096

Review 4.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

5.  Validation of various osteoporosis risk indices in elderly Chinese females in Singapore.

Authors:  S-P Chan; C C Teo; S A Ng; N Goh; C Tan; M Deurenberg-Yap
Journal:  Osteoporos Int       Date:  2006-05-13       Impact factor: 4.507

6.  Awareness and health beliefs of women towards osteoporosis.

Authors:  Seang-Mei Saw; Ching-Ye Hong; Jeanette Lee; Mee-Lian Wong; Mei-Fen Chan; Angela Cheng; Keng-Hong Leong
Journal:  Osteoporos Int       Date:  2003-06-26       Impact factor: 4.507

7.  The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study.

Authors:  A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi
Journal:  Osteoporos Int       Date:  2007-10-09       Impact factor: 4.507

Review 8.  Patterns of bone mineral density testing: current guidelines, testing rates, and interventions.

Authors:  Charles A Morris; Danielle Cabral; Hailu Cheng; Jeffrey N Katz; Joel S Finkelstein; Jerry Avorn; Daniel H Solomon
Journal:  J Gen Intern Med       Date:  2004-07       Impact factor: 5.128

9.  Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process.

Authors:  Susan B Jaglal; Warren J McIsaac; Gillian Hawker; June Carroll; Liisa Jaakkimainen; Suzanne M Cadarette; Cathy Cameron; Dave Davis
Journal:  Osteoporos Int       Date:  2003-07-22       Impact factor: 4.507

Review 10.  Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials.

Authors:  Monika Kastner; Sharon E Straus
Journal:  J Gen Intern Med       Date:  2008-10-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.